Receive The Newest Study Notifications

COVID-19 Pandemic Impact at Clinical Sites Delays Study MENLO PARK, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy...

- Phase 2 study data show the potential for rilonacept treatment to eliminate or reduce the risk of corticosteroid-associated morbidity in recurrent pericarditis - - Enrollment complete for the pivotal Phase 3 trial of rilonacept in recurrent pericarditis (RHAPSODY);...

A phase II trial of ficlatuzumab (AV-299), an investigational HGF inhibitory antibody, in patients with relapsed and refractory acute myeloid leukemia (AML) joins the growing list of clinical trials halted due to the coronavirus disease 2019 (COVID-19) pandemic....

Due to the global spread of the Sars-cov-2 virus Cereno Scientific announces that the company will postpone the planned Phase II clinical trial with the company’s lead compound CS1. The start of the study was previously planned for mid-year 2020. Cereno Scientific is...

Atlanta, GA – Emory Healthcare announced that its Vaccine and Treatment Evaluation Unit will be a part of clinical testing a COVID-19 vaccine. “The goals of the Phase I study, which began on March 16 at the VTEU at the Kaiser Permanente Washington Health Research...

CAMBRIDGE, Mass. & BOULDER, Colo.--(BUSINESS WIRE)--Mar. 27, 2020-- AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the discontinuation of their CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte...

Dublin, March 27, 2020 (GLOBE NEWSWIRE) -- The "Market Spotlight: Acne (2020)" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the Acne market, comprising key marketed and pipeline drugs, recent events and analyst...

ERT’s At-Home Cardiac Safety Assessment Ensures Clinical Trial Continuity Company’s expertise, infrastructure and flexibility enable remote ECG assessment for fast-tracked COVID-19 vaccines /therapies and other critical pharmaceuticals PHILADELPHIA – March 30, 2020...

The University of Alabama at Birmingham will take part in an NIH-sponsored global clinical trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized adult patients diagnosed with COVID-19. The drug remdesivir is the first agent to be...

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today it is implementing an interim analysis of the Phase III...

Mitigating the Impact on Site Monitoring Efforts Due to Covid-19 KING OF PRUSSIA, PA, US - Mar 18, 2020 - CluePoints, the premier provider of Risk-Based Trial Execution (RBx) and Data Quality Oversight Software for clinical trials, today announced that it has seen a...

Ergomed’s PrimeVigilance Announces Provision of Clinical Safety Services for COVID-19 Clinical Trial Program Guildford, UK – 30 March 2020: Ergomed plc (ERGO.L) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical...

The COVID-19 pandemic continues to dominate the news and is likely to for quite some time. The biopharma industry is doing what it can to test and repurpose therapies, develop diagnostics and respond to the crisis. Also, although some clinical trials are being slowed...

Farxiga is the first SGLT2 inhibitor to show meaningful benefit in patients with chronic kidney disease in a trial including both type-2 diabetics and non-diabetics The Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) Phase III...

Crucial life-saving initiative led by Dr. Steven Quay for clinical trials on the safety and efficacy of a combination of FDA-approved drugs (nebulized Heparin-N-acetylcysteine in COVID-19 Patients by Evaluation of pulmonary function (HOPE)) SEATTLE, March 30, 2020...

PARIS and TARRYTOWN, N.Y. – March 30, 2020 – The first patient outside of the U.S. has been treated as part of a global clinical program evaluating Kevzara® (sarilumab) in patients hospitalized with severe COVID-19. The global clinical program has now been initiated...

The Covid-19 pandemic has shined a bright light on the need to manage patients remotely wherever possible. This need is especially acute in clinical trials as identified by the FDA. Trial sponsors, physicians and regulators are now embracing the use of technology to...

SUZHOU, China, and ROCKVILLE, Md., March 23, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today...

ENGLEWOOD, Colo., March 24, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE; the "Company"), a pre-revenue development stage biopharmaceutical company announced today that it has suspended patient enrollment in its Phase 3 clinical trial of...

COVID-19 task force established to support enrolled patients Participating medical centers implemented safety measures and currently enrolling patients Cranbury, NJ, March 24, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader...